Uro-genital condition treatment system

Abstract

The present invention is directed to a system for treating uro-genital conditions. One aspect of this invention involves the treatment system comprising one or more polypeptides with a amino acid sequence including KPV (SEQ. ID. NO. 1), MEHFRWG (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), for treatment of uro-genital conditions. The one or more polypeptides can also be a dimer formed from any of the amino acid sequence above. Uro-genital conditions can include infections, inflammation, or both. In one preferred embodiment of the invention, the uro-genital condition includes infection and/or inflammation of the vagina, vulva, urinary tract, penis, and/or the rectum. In another preferred embodiment of the invention, the one or more polypeptides are dissolved in a carrier. In another preferred embodiment of the invention, the one or more polypeptides are associated with a tampon for preventing toxic shock syndrome. In another preferred embodiment, the one or more polypeptides are associated with a contraceptive for prevention of sexually transmitted diseases or infections. In another preferred embodiment, the one or more polypeptides are associated with a suppository for insertion into the vagina or rectum.

1 . A method of treating vaginitis comprising: 
 administering a therapeutic amount of a polypeptide including an amino acid sequence KPV at C-terminus to an individual in need thereof.    
     
     
         2 . The method of  claim 1  wherein the polypeptide includes at least one amino acid in D-form.  
     
     
         3 . The method of  claim 1  wherein the amino acid sequence KPV is located at a C-terminal of the polypeptide.  
     
     
         4 . The method of  claim 1  wherein the polypeptide is N-acetylated or C-amidated or both.  
     
     
         5 . The method of  claim 1  wherein the polypeptide is administered with a carrier.  
     
     
         6 . The method of  claim 1  wherein the polypeptide is administered as a gel.  
     
     
         7 . The method of  claim 1  wherein the polypeptide is administered in a form selected from a group consisting of ointment, foam, balm, cream, dissolvable pill, aerosol spray, aerosol foam and liquid solution of a douche.  
     
     
         8 . The method of  claim 1  wherein the polypeptide is administered with an applicator.  
     
     
         9 . The method of  claim 8  wherein the applicator is selected from the group consisting of syringes, bandages, catheters, and spatulas.  
     
     
         10 . The method of  claim 8  wherein at least a part of the applicator is for insertion into a vagina.  
     
     
         11 . The method of  claim 1  wherein the vaginitis is caused by a bacterial infection.  
     
     
         12 . The method of  claim 11  wherein the bacterial infection is caused by  Staphylococcus aureus.    
     
     
         13 . The method of  claim 1  wherein the vaginitis is caused by a fungal infection.  
     
     
         14 . The method of  claim 13  wherein the fungus is Candida sp.  
     
     
         15 . The method of  claim 14  wherein the fungus is  Candida albicans.    
     
     
         16 . The method of  claim 1  wherein the vaginitis is caused by a viral infection.  
     
     
         17 . A method of treating vaginitis comprising: 
 administering a therapeutic amount of a dimer to an individual in need thereof wherein the dimer comprises KPV at C-terminus.    
     
     
         18 . The method of  claim 17  wherein the dimer is a homodimer.  
     
     
         19 . The method of  claim 17  wherein the dimer is a heterodimer.  
     
     
         20 . The method of  claim 17  wherein at least one amino acid is in D-form.  
     
     
         21 . The method of  claim 17  wherein the dimer is N-acetylated or C-amidated or both.  
     
     
         22 . The method of  claim 17  wherein the dimer comprises two monomers linked together by a disulfide bond and wherein each monomer comprises KPV.  
     
     
         23 . The method of  claim 17  wherein the dimer comprises two monomers wherein each monomer has a C-terminal Cysteine wherein the C-terminal Cysteine links the monomers together by a disulfide bond and wherein each monomer is KPV.  
     
     
         24 . The method of  claim 17  wherein the dimer is administered with a carrier.  
     
     
         25 . The method of  claim 17  wherein the dimer is administered in the form of a gel.  
     
     
         26 . The method of  claim 17  wherein the dimer is administered in a form selected from a group consisting of ointment, foam, balm, cream, dissolvable pill, aerosol spray, aerosol foam and liquid solution of a douche.  
     
     
         27 . The method of  claim 17  wherein the dimer is administered with an applicator.  
     
     
         28 . The method of  claim 27  wherein the applicator is selected from the group consisting of syringes, bandages, catheters, and spatulas.  
     
     
         29 . The method of  claim 27  wherein at least a part of the applicator is for insertion into a vagina.  
     
     
         30 . The method of  claim 17  wherein the vaginitis is caused by a bacterial infection.  
     
     
         31 . The method of  claim 30  wherein the bacterium is  Staphylococcus aureus.    
     
     
         32 . The method of  claim 17  wherein the vaginitis is caused by a fungal infection.  
     
     
         33 . The method of  claim 32  wherein the fungus is from the genus Candida sp.  
     
     
         34 . The method of  claim 33  wherein the fungus is  Candida albicans.    
     
     
         35 . The method of  claim 17  wherein the vaginitis is caused by a viral infection.  
     
     
         36 . A method for treating a yeast infection comprising: 
 administering a therapeutically effective amount of a composition to an area having a yeast infection wherein the composition comprises: 
 a polypeptide having the amino acid sequence KPV at C-terminus; and  
 a carrier.  
   
     
     
         37 . The method of  claim 36  wherein the yeast infection is caused by  Candida albicans.    
     
     
         38 . The method of  claim 36  wherein the carrier includes a gel.  
     
     
         39 . The method of  claim 37  wherein the composition further comprises an applicator.  
     
     
         40 . A method for treating a yeast infection comprising: 
 administering to an area having the yeast infection a therapeutically effective amount of a composition comprising: 
 a dimer wherein the dimer comprises KPV at C-terminus; and  
 a carrier.  
   
     
     
         41 . The method of  claim 46  wherein the carrier includes a gel.  
     
     
         42 . The method of  claim 41  wherein the composition further comprises an applicator.  
     
     
         43 . A method for treating a fungal, bacterial or viral infection comprising: 
 administering to an area having the infection, a therapeutically effective amount of a composition comprising: 
 a polypeptide having the amino acid sequence KPV at C-terminus; and  
 a carrier.  
   
     
     
         44 . The method of  claim 43  wherein the polypeptide further comprises a dimer.  
     
     
         45 . The method of  claim 43  wherein the carrier includes a gel.  
     
     
         46 . The method of  claim 40  wherein the composition further comprises an applicator.